Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis
Numerous clinical studies published in the Chinese language support the use of Medilac-S (<i>Bacillus subtilis</i> R0179 and <i>Enterococcus faecium</i> R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Gastroenterology Insights |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7422/14/4/36 |
| _version_ | 1797380971473928192 |
|---|---|
| author | Annie Tremblay Xiaoyu Xu James Colee Thomas A. Tompkins Sylvie Binda |
| author_facet | Annie Tremblay Xiaoyu Xu James Colee Thomas A. Tompkins Sylvie Binda |
| author_sort | Annie Tremblay |
| collection | DOAJ |
| description | Numerous clinical studies published in the Chinese language support the use of Medilac-S (<i>Bacillus subtilis</i> R0179 and <i>Enterococcus faecium</i> R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel syndrome, acute gastritis, and <i>Helicobacter pylori</i> therapy. This systematic review with a meta-analysis was conducted to summarize clinical studies evaluating the efficacy of this probiotic formulation as an adjuvant to conventional IBS medications. The systematic literature searches in six international and Chinese databases identified 37 eligible studies, of which 33 reported the efficacy of Medilac-S adjunctive therapy using a standardized categorical scale. These 33 studies were included in the meta-analysis using a random-effect model with a stratification by IBS subtype. Overall, Medilac-S significantly improved the efficacy of conventional IBS treatment (RR = 1.21; 95% CI: 1.17–1.25; and <i>p</i> < 0.0001) with an average probability of treatment effectiveness being 21% higher with the probiotic adjuvant, regardless of the subtype. Adverse events, reported in 78% of the trials, were described as mild-to-moderate and self-resolving, with a similar incidence in the probiotic adjuvant (6.2%; n = 1347) and control (5.9%; n = 1331) groups. The results of this meta-analysis strengthen the conclusions that Medilac-S is a safe and effective adjuvant to a variety of conventional treatments in IBS patients. |
| first_indexed | 2024-03-08T20:44:40Z |
| format | Article |
| id | doaj.art-4a75bf62e5554e9d9a7a525806aefe44 |
| institution | Directory Open Access Journal |
| issn | 2036-7414 2036-7422 |
| language | English |
| last_indexed | 2024-03-08T20:44:40Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gastroenterology Insights |
| spelling | doaj.art-4a75bf62e5554e9d9a7a525806aefe442023-12-22T14:10:30ZengMDPI AGGastroenterology Insights2036-74142036-74222023-10-0114449151410.3390/gastroent14040036Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-AnalysisAnnie Tremblay0Xiaoyu Xu1James Colee2Thomas A. Tompkins3Sylvie Binda4Rosell® Institute for Microbiome and Probiotics, Lallemand Health Solutions, 6100 Royalmount Avenue, Montreal, QC H4P 2R2, CanadaRosell® Institute for Microbiome and Probiotics, Lallemand Health Solutions, 6100 Royalmount Avenue, Montreal, QC H4P 2R2, CanadaIFAS Statistical Consulting Unit, University of Florida, P.O. Box 110500, Gainesville, FL 32611-0500, USALallemand Bio-Ingredients, 1620 Rue Prefontaine, Montreal, QC H1W 2N8, CanadaRosell® Institute for Microbiome and Probiotics, Lallemand Health Solutions, 6100 Royalmount Avenue, Montreal, QC H4P 2R2, CanadaNumerous clinical studies published in the Chinese language support the use of Medilac-S (<i>Bacillus subtilis</i> R0179 and <i>Enterococcus faecium</i> R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel syndrome, acute gastritis, and <i>Helicobacter pylori</i> therapy. This systematic review with a meta-analysis was conducted to summarize clinical studies evaluating the efficacy of this probiotic formulation as an adjuvant to conventional IBS medications. The systematic literature searches in six international and Chinese databases identified 37 eligible studies, of which 33 reported the efficacy of Medilac-S adjunctive therapy using a standardized categorical scale. These 33 studies were included in the meta-analysis using a random-effect model with a stratification by IBS subtype. Overall, Medilac-S significantly improved the efficacy of conventional IBS treatment (RR = 1.21; 95% CI: 1.17–1.25; and <i>p</i> < 0.0001) with an average probability of treatment effectiveness being 21% higher with the probiotic adjuvant, regardless of the subtype. Adverse events, reported in 78% of the trials, were described as mild-to-moderate and self-resolving, with a similar incidence in the probiotic adjuvant (6.2%; n = 1347) and control (5.9%; n = 1331) groups. The results of this meta-analysis strengthen the conclusions that Medilac-S is a safe and effective adjuvant to a variety of conventional treatments in IBS patients.https://www.mdpi.com/2036-7422/14/4/36probioticsirritable bowel syndromeMedilac-Smeta-analysissystematic review |
| spellingShingle | Annie Tremblay Xiaoyu Xu James Colee Thomas A. Tompkins Sylvie Binda Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis Gastroenterology Insights probiotics irritable bowel syndrome Medilac-S meta-analysis systematic review |
| title | Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis |
| title_full | Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis |
| title_fullStr | Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis |
| title_full_unstemmed | Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis |
| title_short | Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis |
| title_sort | effectiveness of medilac s as an adjuvant to conventional irritable bowel syndrome treatments a systematic review with meta analysis |
| topic | probiotics irritable bowel syndrome Medilac-S meta-analysis systematic review |
| url | https://www.mdpi.com/2036-7422/14/4/36 |
| work_keys_str_mv | AT annietremblay effectivenessofmedilacsasanadjuvanttoconventionalirritablebowelsyndrometreatmentsasystematicreviewwithmetaanalysis AT xiaoyuxu effectivenessofmedilacsasanadjuvanttoconventionalirritablebowelsyndrometreatmentsasystematicreviewwithmetaanalysis AT jamescolee effectivenessofmedilacsasanadjuvanttoconventionalirritablebowelsyndrometreatmentsasystematicreviewwithmetaanalysis AT thomasatompkins effectivenessofmedilacsasanadjuvanttoconventionalirritablebowelsyndrometreatmentsasystematicreviewwithmetaanalysis AT sylviebinda effectivenessofmedilacsasanadjuvanttoconventionalirritablebowelsyndrometreatmentsasystematicreviewwithmetaanalysis |